Long chain acyl-CoA synthase-4 (ACSL4) expression has been associated with an aggressive phenotype in breast carcinoma cells, whereas its role in ERα-positive breast cancer has not been studied. ACSL4 prefers 20-carbon polyunsaturated fatty acid (PUFA) substrates, and along with other ACSLs has been associated with cellular uptake of exogenous fatty acids. 17β-estradiol induces proliferation and invasive capacities in ERα+ve breast carcinoma that is associated with modifications of cellular lipid metabolism. In this study, treatment of steroid-starved ERα-positive MCF-7 and T47D mammary carcinoma cells with 17β-estradiol resulted in increased cellular uptake of the PUFA arachidonic acid (AA) and eicosapentaenoic acid (EPA), important building blocks for cellular membranes, and increased ACSL4 protein levels. There was no change in the expression of the ACSL1, ACSL3 and ACSL6 protein isotypes. Increased ACSL4 protein expression was not accompanied by changes in ACSL4 mRNA expression, but was associated with a significant increase in the protein half-life compared to untreated cells. ERα silencing reversed the impact of 17β-estradiol on ACSL4 protein levels and half-life. Silencing of ACSL4 eliminated the 17β-estradiol-induced increase in AA and EPA uptake, as well as the 17β-estradiol-induced cell migration, proliferation and invasion capacities. ASCL4 silencing also prevented the 17β-estradiol induced increases in p-Akt and p-GSK3β, and decrease in E-cadherin expression, important events in epithelial to mesenchymal transition. Taken together, these results demonstrate that ACSL4 is a target of 17β-estradiol-stimulated ERα and is required for the cellular uptake of exogenous PUFA and the manifestation of a more malignant phenotype in ERα+ve breast carcinoma cells.
Introduction
With their multiple biological roles, lipids contribute to several aspect of cancer biology such as energy homeostasis and cellular proliferation (1) . To support cell proliferation, cancer cells including mammary carcinoma cells exhibit a shift toward fatty acid (FA) biosynthesis whose importance is demonstrated by the induction of apoptosis upon the inhibition of lipogenic enzymes (1) (2) (3) (4) (5) . Many enzymes implicated in lipogenesis such as fatty acid synthetase and stearoyl-CoA desaturase (SCD-1) have been recognized as key players in breast cancer progression (6) (7) (8) . For example, the silencing of fatty acid synthetase in breast carcinoma cells arrests cellular growth and induces apoptosis without toxicity to proliferating normal cells (5) . For SCD-1, the principal provider of monounsaturated fatty acids (MUFA) required for membrane biogenesis, its expression is enhanced in many carcinomas including breast cancer and is required for the maintenance of cell proliferation and tumor formation (8) (9) (10) (11) (12) . Accordingly, SCD-1 expression and activity are enhanced in estrogen-dependent breast carcinoma cells upon treatment with mitogenic 17β-estradiol via the activation of the transcription factor SREBP-1c (13) .
Like MUFA, polyunsaturated fatty acids (PUFA) are essential to ensure proper membrane fluidity required for the appropriate functions of newly synthesized cellular membranes. However, the principal source of cellular PUFA is exogenous since these FA are, for the most part, essential cellular nutrients. A family of proteins that can participate in the cellular uptake of exogenous fatty acids are the acyl-CoA synthetases (ACS) (14, 15) . In humans, the long chain ACS (ACSL) that prefer substrates with carbon chains ranging form 12 to 20 carbons are comprised of five enzymes where each isoform differs by its cellular location and/or substrate specificity (16) (17) (18) . The ACSL4 isoform prefers longer chain highly unsaturated PUFA substrates like the 20-carbon arachidonic acid (AA) and eicosapentaenoic acid (EPA), catalyzing their conversion to AA-CoA and EPA-CoA (17, 19) . ACSL4 is expressed in several cancer cell lines and has emerged as an interesting therapeutic target since its inhibition reduces cell invasion and migration and induces apoptotic cell death in colon, prostate, breast, lung and brain cancer cells (2, (20) (21) (22) .
In breast carcinoma tissue ACSL4 mRNA expression correlates negatively with the estrogen receptor-α (ERα), with higher expression measured in aggressive triple negative tumors, and is associated with decreased time to distant metastasis in patients with ER−ve tumors (21, 23) . However, these relationships are based only on mRNA expression and not ACSL4 protein levels that have been shown to not necessarily correlate with gene expression (24, 25) . In the few mammary carcinoma cell lines in which ACSL4 has been investigated, the aggressive ERα−ve MDA-MB-231 and Hs578T cell lines highly express ACSL4 protein and ACSL4 silencing reduces their proliferation, migration and invasive capacities (23, 26) . Conversely, the ERα+ve mammary MCF-7 and T47D carcinoma cells express ACSL4 mRNA and protein more weakly and its overexpression in these cell lines with the use of expression vectors is associated with a more aggressive phenotype including an enhanced capacity to form tumors in vivo (23, 26, 27) . However, the regulation and role of endogenous ACSL4 expression in ERα+ve cells has not been investigated.
Given that the generation of MUFA through fatty acid synthesis and desaturation pathways is required for estrogen-driven proliferation of hormone-sensitive breast carcinoma cells (13) , in this study we set out to elucidate the impact of 17β-estradiol on ACSL4 expression and PUFA uptake in hormone-sensitive MCF-7 and T47D cells. We show herein that 17β-estradiol induces ACSL4 protein levels that is required for enhanced cellular PUFA uptake and the induction of a more aggressive cellular phenotype in breast carcinoma cells.
Materials and methods

Cell culture
Authenticated MCF-7, T47D and MCF-10A cell lines were purchased from ATCC (Manassas, VA). Frozen aliquots were stored and after thawing not cultured for longer than 5 months. MCF-7 and T47D cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a humidified 5% CO 2 atmosphere. MCF-10A cells were cultured as above except DMEM/F12 medium was used with 5% FBS and 100 ng/ml cholera toxin. Before treatments cells were cultured for one week in phenol red-free medium supplemented with 10% charcoal-stripped FBS (5% for MCF-10A cells) to starve cells from steroid hormones (starvation medium) (13, 28, 29) . Cells were then treated with 2 nM 17β-ED or its vehicle for 5 days as previously reported (13) in the presence or absence of indicated reagents.
Transient ERα and ACSL4 siRNA silencing
Transient transfections were carried out using the Gene Pulser XCell from Bio-Rad. MCF-7 cells (2 × 10 6 cells) that had been starved as above for 5 days were resuspended in 200 μl phenol red-free RPMI to which was added 4 μl of siRNA targeting ERα (Cat#301461) or ACSL4 (Cat # SR-301523) from OriGene (Rockville, MD) for a final concentration of 100 nM or a nontargeting duplex of the same length as negative control (Cat # SR-30004). Cells were subjected to electroporation using a single 300 V pulse with a capacitance of 250 μF. Cells were then seeded in starvation medium (without antibiotics) containing 2 nM 17β-ED or its vehicle. After three days, cells were collected for further analyses.
Fatty acid uptake
After transfection and 17β-ED treatment, the counted and trypsinized cells were incubated in 1 ml of culture medium containing 1 μCi [ 3 H]AA (American Radiolabels), 1 μCi [ 3 H]18:1n-9 (Moravek Biochemicals) or 0.1 μCi [ 14 C]EPA (American Radiolabels) for 40 min at 37°C. Cells were then washed twice with culture medium and resuspended in 800 μl phosphate-buffered saline, then cellular lipids were extracted (30) . Briefly, to the resuspended cells 3 ml of chloroform: methanol (1:2, v:v) and 25 µl of 10% acetic acid were added to each sample. Samples were vortexed and left at room temperature for 15 min. Another 2 ml of chloroform and 1 ml of water were then added, the samples were centrifuged at 180 × g for 2 min and the organic layer containing lipids was transferred to a clean tube. Another 2 ml of chloroform was then added, and after centrifugation the bottom layer was pooled with the first extract of lipids. Extract was evaporated under a stream of N 2 and the cellular radioactivity was measured by liquid scintillation counting using a Beckman Instruments LS 5000 counter.
RNA extraction and qPCR
Cellular mRNA was extracted with Trizol (Invitrogen) and purified with the RNeasy Mini Kit (Qiagen). cDNA was prepared from mRNA using the Quantitect reverse transcription kit according to the manufacturer's protocol (Qiagen). Gene expression was measured using 25 ng of cDNA by quantitative PCR (ABI 7500, Applied Biosystems) with Perfecta TM Supermix Low ROX (Quanta Biosciences Inc.). The primers for ACSL4 (154bp) were forward-5′-ACCCAGCCACACAAACAGGAGATA-3′ and reverse-5′-AAACGTAGTGTCCACGGCACTCAA-3′ and the probe was 5′/56-FAM/ TGGTCCATC/ZEN/GCAGATAAGCGTGTGGAAA/3IABkFQ/-3′. The primers for the reference genes were forward-5′-GAGACTCTGGCATGCTAA CTAG-3′ and reverse-5′-GGACATCTAAGGGCATCACAG-3′ for RN18S1, and forward-5′-TGCTGAGGATTTGGAAAGGG-3′ and reverse-5′-TTTATG TCCCCTGTTGACTGG-3′ for HPRT. The probe sequences were 5′/56-FAM/ TGCTCAATC/ZEN/TCGGGTGGCTGAA/3IABkFQ/3′ and 5′/56-FAM/AGATGT GAT/ZEN/GAAGGAGATGGGAGGC/3IABKFQ/-3′ for RN18S1 and HPRT, respectively. The efficiency of the primer pairs was evaluated using a standard curve and the stability of the expression of the RN18S1 or HPRT reference genes between treatments was evaluated.
ACSL4 mRNA half-life measurement
To determine ACSL4 mRNA half-life, starved MCF-7 cells were treated or not with 2 nM 17β-ED or its vehicle for 5 days as described above. Cells were incubated in the presence of Actinomycin D (5 μg/ml) for different times up to 7 h. At the end of incubation, total RNA was extracted from the cells and ACSL4 mRNA expression was assessed using qPCR as described above.
Western blots
For gel electrophoresis, 75 μg of proteins were loaded on a 4-15% polyacrylamide Criterion gel from Bio-Rad. After migration proteins were electrotransfered to PVDF membranes (GE Healthcare) that were then blocked in 10% non-fat dry milk in TBS-Tween. Western blotting was then performed using anti-ACSL1, anti-ACSL3, anti-ACSL4, anti-ACSL6, anti-Akt and anti-phospho Akt (ser473) purchased from Abcam (ab178419, ab151959, ab155282, ab179647, ab32505 and ab81283, respectively), anti-GSK3β, anti-phospho GSK3α/β (ser21/9) and anti-E-cadherin from Cell Signaling (catalogue numbers 9315S, 9331S and 3195S, respectively), and anti-β-actin from SigmaAldrich (A3854 were from Sigma-Aldrich. The immunoblots were visualized using ECL prime (GE Healthcare) and an Alpha Innotech Fluorochem imager (San Leandro, USA). The densitometry of each immunoblot was performed using Alpha Ease Fluorochem software.
ACSL4 protein half-life determination
MCF-7 cells subjected to the indicated treatments were incubated with 5 μg/ml cycloheximide (CHX) for different times up to 24 h. To determine the half-life of ACSL4, 75 μg of protein from CHX-treated cells were subjected to SDS-PAGE followed by immunoblotting for ACSL4 and β-actin and quantitated. For each experiment, the amount of ACSL4 at t = 0 was set to 100, and the normalized signals at different time points were plotted against time and fitted to an exponential decay curve and the half-life (T 1/2 ) was calculated using GraphPad Prism 5 software.
In vitro cell migration and invasion assays
For cell migration assays, newly transfected and treated MCF-7 and T47D cells were plated in six-well plates. Twelve hours post transfection the cell monolayer was scratched in the bottom of each well followed by a replacement of culture medium. The cells were monitored for three days with a Zeiss observer A1 microscope and the distance between the scratched borders was measured using the free software Image J (31). Cell proliferation was assessed by staining cells in 0.2% trypan blue and counting viable cells using a hemocytometer. For cell invasion assays, transwell inserts were coated with 5 mg/ml of Matrigel (BD Biosciences) and incubated for 16 h at 37°C. Cells were suspended in 400 μl of phenol-free RPMI without FBS and were added to each transwell. Transwells were then transferred to wells containing phenol redfree RPMI media supplemented with 20% charcoal-stripped FBS and incubated at 37 0 C. After 48h, invading cells were trypsinized and quantified using a Cell Titer Blue kit from Promega, following the manufacturer's instructions.
Statistical analyses
Data are representative of three or more independents experiments. Differences between treatments were analyzed using Student's t-test or 1-way ANOVA tests with Tukey's post-hoc test, performed with GraphPad Prism Version 6.0 software.
Results
17β-ED-induced cellular PUFA uptake and ACSL4 protein expression
In this study ERα+ve MCF-7 and T47D breast carcinomas cells and the immortalized MCF-10A normal mammary epithelial cell line were used to study the effect of 17β-ED on PUFA uptake. The three cell lines were starved with phenol red-free media supplemented with charcoal-stripped FBS followed by the addition of 2 nM 17β-ED that increases cell proliferation in both MCF-7 and T47D but not in normal immortalized MCF-10A using an established protocol (13) . 17β-ED also induces de novo fatty acid synthesis and desaturation in breast carcinoma cells to support new membrane synthesis associated with cell proliferation (13) . To study the impact of 17β-ED treatment on the ability of cells to incorporate exogenous PUFA, cells were incubated with exogenous [ 3 H]AA and [
14 C]EPA and cellular AA and EPA uptake were measured. Incubation of both breast carcinomas cell lines with 17β-ED was associated with an increase in cellular uptake of AA and its ω-3 homolog EPA ( Figure 1A and B) . No changes in AA or EPA uptake were observed in estrogen non-sensitive MCF-10A cells, consistent with the lack of 17β-ED-induced cell proliferation in these cells.
ACSL enzymes have been associated with the ability of cells to incorporate exogenous fatty acids including PUFA. Therefore, the protein levels of members of the ACSL family were measured in the three cell lines incubated in the absence or presence of 17β-ED. Amongst the ACSL isotypes, only ACSL4 protein expression was increased in 17β-ED treated MCF-7 and T47D mammary carcinomas cells (Figure 2A and B) compared to nontreated controls, while the other ACSL family members ACSL1, ACSL3 and ACSL6 were expressed but unchanged by 17β-ED treatment in both cell lines. In MCF-10A cells, all measured isotypes were expressed but no changes in protein levels were measured following 17β-ED treatment ( Figure 2C ).
To determine whether the 17β-ED-induced increase in ACSL4 protein levels was associated with activation of the ERα receptor, ERα silencing experiments were performed using three different siRNAs targeting ERα in MCF-7 and T47D cells. ERα expression was effectively suppressed by the three siRNA in both cell lines and this was associated with a loss in the ability of 17β-ED to induce ACSL4 protein expression indicating that the induction of ACSL4 is ERα dependent (Figure 3A-D) .
Since ERα activation by 17β-ED has been shown to induce gene expression of lipogenic enzymes in mammary carcinomas cells (13, 32) , ACSL4 mRNA expression was measured in both MCF-7 and T47D cells in response to 17β-ED. However, no difference in ACSL4 mRNA levels was observed between 17β-ED-treated and control cells ( Figure 3E ). Consistent with the absence of an effect of 17β-ED on mRNA content, the stability of ACSL4 mRNA was not affected by 17β-ED treatment in MCF-7 cells ( Figure 3F ).
17β-ED extends ACSL4 protein half-life
Given the lack of an effect of 17β-ED on ACSL4 mRNA levels, protein stability of ACSL4 was evaluated by monitoring ACSL4 protein levels for 24 h after treatment with the protein synthesis inhibitor CHX. In 17β-ED treated MCF-7 cells, the level of ACSL4 protein expression decreased significantly more slowly over the 24h treatment period compared to untreated control cells ( Figure 4A ) where 17β-ED treatment extended the ACSL4 half-life from 7.5 ± 0.5 h in control cells to 26 ± 2 h in 17β-ED-treated cells. To support these findings that the extended half-life is ERα-dependent, ACSL4 protein half-life was assessed in 17β-ED-treated MCF-7 cells pretransfected with a non-silencing siRNA or a specific ERα-silencing siRNA. ERα silencing eliminated the 17β-ED-induced increase of the ACSL4 protein half-life whereas the increase in half-life was maintained in 17β-ED-treated MCF-7 cells that has been transfected with non-silencing siRNA ( Figure 4B) .
To investigate the mechanism by which ACSL4 half-life is extended by 17β-ED treatment, cellular proteasomal function was inhibited by incubating 17β-ED treated and untreated MCF-7 cells for 12 h with the proteasome inhibitor MG132 (Sigma) prior to cell lysis and ACSL4 protein measurement. Treatment of cells with MG132 increased ACSL4 protein levels in control cells but had no effect on ACSL4 in 17β-ED treated MCF-7 cells ( Figure 4C ). These results strongly suggest that in ERα+ve carcinoma cells, 17β-ED enhanced ACSL4 protein levels by prolonging ACSL4 protein half-life as a result of a decrease of its rate of proteasomal degradation.
ACSL4 is necessary for 17β-ED-induced PUFA uptake in mammary carcinomas cells
To assess the role of ASCL4 in cellular PUFA uptake, ACSL4 silencing experiments were first performed in 17β-ED treated MCF-7 and T47D cells. Two siRNA targeting ACSL4 were shown to effectively decrease ACSL4 protein levels in both MCF-7 and T47D cells as assessed by western blot (Figure 5A and B). ACSL4 silencing was then used to address the role of ACSL4 on the capacity of 17β-ED to increase cellular AA and EPA uptake from extracellular media. As shown in Figures 5C-F , the 17β-EDinduced increase the capacity to incorporate extracellular AA and EPA in MCF-7 and T47D cells is dependent on the increase in ACSL4 levels. Interestingly, 17β-ED treatment did not impact on the capacity of cells to take-up exogenous oleic acid (18:1 n-9) ( Figure 5G-H) suggesting that 17β-ED induction of ACSL4 only impacted the uptake of PUFA with no effect on cellular MUFA uptake. 
ACSL4 is involved in 17β-ED-induced cell migration, proliferation, invasion and EMT signaling
To further explore the potential role of ACSL4 in 17β-ED-treated mammary carcinomas cells, the effects of ACSL4 silencing on 17β-ED induced migration and invasion were measured. Using the scratch cell migration assay, 17β-ED-treated MCF-7 and T47D cells showed a significant increase in cell migration compared to their non-treated controls over 48-72 hours. ACSL4 silencing had no impact on cell migration in control cells incubated in the absence of 17β-ED (data not shown), however ACSL4 silencing completely reversed 17β-ED-induced cell migration in both cell lines ( Figure 6A ). Since the scratch assay can partially be a function of cell proliferation, cells were counted and ACSL4 silencing also impacted on cell counts ( Figure 6B ) indicating that the impact on migration as measured by the scratch test is at least partially explained by a decrease in cell proliferation.
Cellular invasion in Matrigel was only assessed in the more aggressive T47D cells since MCF-7 cells exhibited very little measurable invasion capacity into Matrigel as previously reported (33) . A significant induction of cell invasion by 17β-ED was measured in T47D cells compared to untreated cells, however, this enhanced invasion capacity was completely reversed by ACSL4 silencing ( Figure 6C ). Together, these results indicate that ACSL4 is implicated in 17β-ED-induced cell migration and invasion capacities, two prerequisites for the EMT induced by 17β-ED.
To investigate signaling events associated with EMT, Akt and GSK3β phosphorylation as well as the protein levels of their downstream target E-cadherin were measured. 17β-ED treatment of T47D cells activated Akt (via phosphorylation) and inhibited GSK3β (via phosphorylation), and decreased E-Cadherin content, important signaling events associated with the induction of EMT ( Figure 6D ). Importantly, ACSL4 silencing prevented the 17β-EDinduced phosphorylation of AKT and GSK3β ( Figure 6D ) without impact on total AKT and GSK3β levels. Additionally, the silencing of ACSL4 prevented the 17β-ED-induced repression of E-cadherin levels ( Figure 6D ). Overall, ACSL4 silencing prevented the phenotypic changes and signaling events associated with EMT that were induced by treatment with 17β-ED.
Discussion
It is well established that the control of metabolism is altered in many cancers compared to normal cells and tissues, and this includes an increase in de novo fatty acid biosynthesis coupled with an enhanced capacity for fatty acid desaturation. Indeed acyl CoA-carboxylase, fatty acid synthase and SCD-1 expression are enhanced in many carcinomas, likely to supply the monounsaturated fatty acids required for proper phospholipid biosynthesis, membrane fluidity and function, and to support membrane biogenesis (3, 34, 35) . Accordingly, in estrogen sensitive breast carcinomas 17β-ED induces SCD-1 expression that is required to maintain cell proliferation (13) . However the fatty acyl composition of cellular membranes also includes significant quantities of PUFA, which are essential nutrients that cannot be synthesized by cells. Although a number of proteins can participate in cellular PUFA uptake (14, 18, 36, 37) , surprisingly little is known regarding the mechanisms associated with the regulation of PUFA uptake by carcinoma cells and there is no information on the impact of 17β-ED on PUFA uptake in ER+ve breast carcinoma cells.
In the current study, a significant increase in the cellular uptake of the highly unsaturated PUFA, AA and EPA, was measured following ERα activation in ERα+ve mammary carcinoma cells, but not immortalized normal mammary epithelial cells. In an effort to explain this previously undescribed cellular response to 17β-ED, the levels of the ACSL family of proteins were measured since these proteins have been associated with the uptake of extracellular fatty acids (14, 15) . ACSLs can contribute to the cellular uptake of fatty acids by entrapping the PUFA in the cell in the form of a more hydrophilic acyl-CoA derivative that is activated for incorporation into glycerophospholipids by acyl-CoA lysophospholipid acyl transferases (14, 38) , thus contributing to phospholipid biosynthesis and remodeling. Amongst the ACSL isoforms measured, only the levels of ACSL4 were enhanced following the treatment of MCF-7 and T47D cells with 17β-ED. Notably, this is the isoform that prefers 20-carbon PUFA as substrates (17, 19) . ERα silencing muted the 17β-EDinduced ACSL4 protein levels strongly suggesting that ERα is necessary for the 17β-ED induction of ACSL4 protein. Notably, ACSL4 silencing eliminated the 17β-ED-induced enhancement of AA and EPA incorporation in MCF-7 and T47D breast carcinoma cells strongly suggesting that ACSL4 was responsible for the enhanced uptake of PUFA in response to 17β-ED. It is well documented that 17β-ED, via the activation of ERα, induces cell migration and invasion capacities that are requisites for the EMT of breast cancer cells that require the activation of signaling pathways including the Akt/GSK3β/Ecadherin axis (39) (40) (41) . Importantly, ACSL4 silencing resulted in an impairment of 17β-ED-induced cellular migration, proliferation and invasion capacities in breast carcinoma cells. Accordingly, the current study also reports for the first time that ACSL4 silencing blocks the 17β-ED induced phosphorylation of AKT and GSK3β, and increases the levels of their downstream target E-cadherin. Thus the 17β-ED-induced activation of Akt, inactivation of GSK3β and increased E-cadherin expression, events consistent with enhanced EMT capacities, are muted when ACSL4 is silenced. This result is consistent with an increase in phospho-Akt and the induction of an invasive phenotype following the ectopic expression of ACSL4 in prostate and breast carcinoma cells (22, 42) . At this time it is not known whether AA-CoA, the main product of ACSL4, is directly responsible for the induction of Akt phosphorylation or whether an ERα-dependent signaling mechanism is abrogated when appropriate membrane assembly or remodeling is not achieved due to a lack of building blocks. This inability to properly assemble membranes due to inadequate PUFA availability would be akin to that observed when MUFA availability is limited in carcinomas following SCD-1 inhibition or silencing, which results in a less aggressive phenotype in vitro and reduced tumor growth in vivo (9, 10, 43) . Taken together, these observations demonstrate that ACSL4 is an essential player associated with ERα-stimulated promotion of invasiveness and migration through the Akt/GSK3β/E-cadherin pathway.
It was previously shown that the forced overexpression of ACSL4 using expression vectors in ERα+ve mammary carcinoma cells results in a more aggressive and invasive phenotype (23, 26, 27, 42) that no longer requires estrogen for growth. Similarly, ACSL4 silencing in highly invasive triple negative MDA-MB-231 cells decreases their aggressive phenotype (23, 26) . In fact, ERα+ve cells express much less ACSL4 than more aggressive cells (21, 23) , and this in combination with low ACSL4 mRNA expression in ERα+ve cells and tissues led to the suggestion that ACSL4 expression only plays a role in the aggressive phenotype of more invasive ERα−ve carcinomas. The current results showing that ACSL4 protein expression is required for the induction of EMT-associated phenotypic changes in response to 17β-ED indicates that this protein also plays a role in ERα+ve cell behavior. Furthermore, previous screening studies of cells and tissues relating ACSL4 expression with phenotypes or clinical outcomes were based on mRNA expression profiles, and the current results clearly show that ERα-dependent induction of ACSL4 protein is independent of gene expression suggesting that ACSL4 mRNA expression is not an appropriate indicator for protein expression as previously shown (24) .
In the absence of an induction of ACSL4 gene expression in response to 17β-ED, the possibility that ACSL4 protein levels increased as a result of changes in protein stability of ACSL4 was investigated. Indeed, ACSL4 has been shown to be regulated by the balance of its product/substrate ratio where the product of ACSL4, AA-CoA, promotes its degradation through the proteasome pathway in HepG2 hepatocarcinoma cells (25) . Accordingly, 17β-ED treatment significantly extended the ACSL4 protein half-life in breast carcinoma cells by reducing the rate of proteasomal degradation. In the current study where enhanced proliferative rates are observed under 17β-ED stimulation, cells would require AA-CoA for the biosynthesis and remodeling of newly synthesized membrane phospholipids. We therefore postulate that in 17β-ED treated cells ACSL4 escapes proteasome degradation because cytoplasmic accumulation of AA-CoA is limited, and in turn the enhanced ACSL4 protein levels provides cells with sufficient building blocks to maintain proper membrane assembly and function.
Finally, forced ACSL4 expression has been associated with enhanced COX-2 expression in breast carcinoma cells (26) . Since COX-2 is known to promote an aggressive phenotype in breast cancer (44) , 17β-ED induction of ACSL4 and the resulting increased capacity to incorporate AA, a COX-2 substrate, could lead to enhanced prostaglandin production thus contributing to an aggressive phenotype. Accordingly, ACSL4 expression also led to the enhanced capacity to incorporate EPA, a PUFA associated with a less aggressive phenotype in exposed cells (45) . Thus AA and EPA may compete for ACSL4 to gain entry into the cell and although ACSL4 expression was associated with a more aggressive phenotype, exposure of cells to EPA may modulate this aggressive phenotype whereas exposure to exogenous AA may further promote it.
Conclusion
In summary, we report here evidence of an induction of ACSL4 protein levels by 17β-ED in ERα positive MCF-7 and T47D breast carcinoma cells. We propose that this induction is caused by a decrease in cellular AA-CoA, an inducer of ACSL4 proteosomal degradation, due to its efficient incorporation into newly synthesized membranes as a result of the enhanced phospholipid biosynthesis and remodeling that accompany cell proliferation. In addition, ACSL4 is also implicated in 17β-ED-induced cellular migration and invasion and the activation of the AKT/GSK3β pathway, all prerequisites for 17β-ED induced EMT.
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